The FDA has approved a new type of medication to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), ...
A new study suggests epigenetic changes at Type 1 diabetes susceptibility genes may explain the risk profile of children born ...
In this latest episode of his “Perry and Friends” podcast, Perry Cohen, Pharm.D., a member of the Managed Healthcare ...
The EMERALD study carries significant implications across multiple stakeholders in ER+/HER2- metastatic breast cancer. For ...
The Infectious Diseases Society of America updates flu and RSV vaccine guidelines, emphasizing safety for immunocompromised patients during respiratory virus season. The Infectious Diseases Society of ...
According to Mark Nestor, M.D., Ph.D., shared with MHE that injecting botulinum toxin in the glabella changes how the amygdala works and stops the brain from getting feedback from frowning, creating a ...
Medicaid provides health coverage for disabled and low-income populations, and the ACA expansion gives states the option to extend coverage to adults with up to 138% of the federal poverty line.
Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...
Improved insurance coverage likely drove increased adoption of Semglee (insulin glargine-yfgn) rather than its status as an interchangeable biosimilar of Lantus, according to new research published in ...
Expert discusses how, despite its importance, albuminuria screening remains underutilized, and improving adherence to dual ...
The FDA has approved Poherdy as the first interchangeable biosimilar to Perjeta, expanding treatment options for adults with HER2-positive breast cancer across both early-stage and metastatic settings ...
Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果